Abstract
Therapeutic strategies based on the insertion of cytokine or other immunostimulatory genes into the genome of tumour cells followed by vaccination with the resulting, genetically modified, cytokine-producing vaccines represent a new potential prospect for the treatment of cancer patients. HPV 16 is the aetiological agent of more than 60 percent human cervical carcinomas (CC). At present, two prophylactic vaccines against HPV 16 are available (GlaxoSmithKline “Cervarix” and Merck “Gardasil”). These vaccines can almost completely protect the immunized individuals against both, persistent HPV 16 infection and HPV 16-related pathological findings in cervical cytology. In contrast, no clinically utilizable therapeutic vaccines against CC are available. During the last decade animal models have substantially contributed to the development of the therapeutic vaccines against HPV 16-associated tumours. It has been demonstrated that the HPV 16 E6/E7 oncoproteins can serve as tumour rejection antigens (TRA) and that the HPV 16-associated tumour cells can be genetically modified with DNA encoding immunostimulatory cytokines (IL-2, IL-12, GM-CSF) or other immunostimulatory molecules, used for vaccination, and inhibit tumour growth. To improve the HPV 16 antigen presentation in tumour-bearing individuals, dendritic cell-based vaccines loaded with HPV 16 E6/E7 DNA or hybrids of the dendritic and tumour cells have also been successfully employed. Unfortunately, when these encouraging approaches used in animal models were translated into clinical trials, the results were less optimistic. The problems that are still to be faced before the therapeutic vaccines against high-risk HPV-associated tumours can be approved for clinical purposes are discussed.
Keywords: HPV 16, genetically modified vaccines
Current Cancer Drug Targets
Title: Genetically Modified Cellular Vaccines for Therapy of Human Papilloma Virus Type 16 (HPV 16)-Associated Tumours
Volume: 8 Issue: 3
Author(s): J. Bubenik
Affiliation:
Keywords: HPV 16, genetically modified vaccines
Abstract: Therapeutic strategies based on the insertion of cytokine or other immunostimulatory genes into the genome of tumour cells followed by vaccination with the resulting, genetically modified, cytokine-producing vaccines represent a new potential prospect for the treatment of cancer patients. HPV 16 is the aetiological agent of more than 60 percent human cervical carcinomas (CC). At present, two prophylactic vaccines against HPV 16 are available (GlaxoSmithKline “Cervarix” and Merck “Gardasil”). These vaccines can almost completely protect the immunized individuals against both, persistent HPV 16 infection and HPV 16-related pathological findings in cervical cytology. In contrast, no clinically utilizable therapeutic vaccines against CC are available. During the last decade animal models have substantially contributed to the development of the therapeutic vaccines against HPV 16-associated tumours. It has been demonstrated that the HPV 16 E6/E7 oncoproteins can serve as tumour rejection antigens (TRA) and that the HPV 16-associated tumour cells can be genetically modified with DNA encoding immunostimulatory cytokines (IL-2, IL-12, GM-CSF) or other immunostimulatory molecules, used for vaccination, and inhibit tumour growth. To improve the HPV 16 antigen presentation in tumour-bearing individuals, dendritic cell-based vaccines loaded with HPV 16 E6/E7 DNA or hybrids of the dendritic and tumour cells have also been successfully employed. Unfortunately, when these encouraging approaches used in animal models were translated into clinical trials, the results were less optimistic. The problems that are still to be faced before the therapeutic vaccines against high-risk HPV-associated tumours can be approved for clinical purposes are discussed.
Export Options
About this article
Cite this article as:
Bubenik J., Genetically Modified Cellular Vaccines for Therapy of Human Papilloma Virus Type 16 (HPV 16)-Associated Tumours, Current Cancer Drug Targets 2008; 8 (3) . https://dx.doi.org/10.2174/156800908784293596
DOI https://dx.doi.org/10.2174/156800908784293596 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regioselective Synthesis of Biologically Important Scaffold Spiro [Indole- Perimidines]: An Antitumor Agents
Letters in Organic Chemistry Polyphenols and Aging
Current Aging Science Physiology of Folic Acid in Health and Disease
Current Drug Metabolism miRNAs in the Biology of Cancers and Viral Infections
Current Medicinal Chemistry Prophylactic Vaccine Approach for Colon and Pancreatic Cancers: Present and Future
Current Medicinal Chemistry Oxytocin and Diabetes Mellitus: A Strong Biochemical Relation. Review
Current Diabetes Reviews Structural and Mechanistic Bases of the Anticancer Activity of Natural Aporphinoid Alkaloids
Current Topics in Medicinal Chemistry Selected Recent Advances in the Synthesis of Bioactive Compounds Using Olefin Metathesis as a Key Step
Current Organic Chemistry Evaluation of High Risk HPV (HPV-16 and -18) RNA and Integration in Cervical Neoplasms in Systemic Lupus Erythematosus
Current Women`s Health Reviews Histone and Non-Histone Targets of Dietary Deacetylase Inhibitors
Current Topics in Medicinal Chemistry Targeting P-glycoprotein for Effective Oral Anti-Cancer Chemotherapeutics
Current Cancer Drug Targets Human Papillomavirus DNA and E6/E7 mRNA Testing as Triage in Liquid-Based Cytology Samples from Primary Screening
Current Pharmaceutical Design Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers
Recent Patents on CNS Drug Discovery (Discontinued) Inflammation and Anemia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Synthesis and Biological Evaluation of a Series of 2-(3,4,5-Trimethoxybenzoyl)-Indol-3-yl Acetic Acid Derivatives as Potential Agents against Human Leukemia K562 Cells
Letters in Drug Design & Discovery Directing Hypoxic Tumor Microenvironment and HIF to Illuminate Cancer Immunotherapy's Existing Prospects and Challenges in Drug Targets
Current Drug Targets Pharmacological Characteristics of Parenteral IGF-I Administration
Current Pharmaceutical Biotechnology Anti-Cancer Therapies that Utilize Cell Penetrating Peptides
Recent Patents on Anti-Cancer Drug Discovery Sublethal Total Body Irradiation Leads to Early Cerebellar Damage and Oxidative Stress
Current Neurovascular Research Patent Analysis as a Tool for Research Planning: Study on Natural Based Therapeutics Against Cancer Stem Cells
Recent Patents on Anti-Cancer Drug Discovery